A call to address penicillin allergy labels in patients with hematopoietic stem cell transplants: How to avoid rash decisions

Abstract Among patients with hematopoietic stem cell transplants, infections, particularly multidrug‐resistant infections, pose a grave threat. In this setting, penicillin allergy labels are both common and harmful. Though the majority of patients who report penicillin allergy can actually tolerate penicillin, penicillin allergy labels are associated with use of alternative antibiotics, which are often more broad spectrum, less effective, and more toxic. In turn, they are associated with more severe infections, multidrug‐resistant infections, Clostridium difficile , and increased mortality. Evaluating penicillin allergy labels can immediately expand access to preferred therapeutic options, which are critical to care in patients with recent hematopoietic stem cell transplants. Point‐of‐care assessment and clinical decision tools now exist to aid the nonallergist in assessment of penicillin allergy. This can aid in expanding use of other beta‐lactam antibiotics and assist in risk‐stratifying patients to determine a testing strategy. In patients with low‐risk reaction histories, direct oral challenges can be employed to efficiently delabel patients across clinical care settings. We advocate for multidisciplinary efforts to evaluate patients with penicillin allergy labels prior to transplantation. image